In Vivo Created CAR T Cells Eliminate Tumors in Mice
Researchers at the University of California, San Francisco, have developed a groundbreaking method for creating CAR T cells in vivo, demonstrating superior efficacy in targeting tumors compared to traditional in vitro approaches. By employing a CRISPR-based system to insert chimeric antigen receptors directly into T cells within the body, this innovative technique successfully eliminated tumors in mice across multiple cancer types, including leukemia and solid tumors.
This advancement is significant for the longevity and healthspan fields, as it addresses key limitations of existing CAR T therapies, such as lengthy preparation times and variable patient outcomes. The in vivo approach not only enhances the functionality and proliferation of T cells but also promises to reduce treatment costs and waiting periods, potentially making these therapies more accessible in community hospitals rather than being confined to specialized centers.
The study underscores the potential for in vivo CAR T cell engineering to revolutionize cancer treatment, paving the way for more efficient and effective immunotherapies that could improve patient outcomes and democratize access to cutting-edge therapies.